Overall, these data support the idea that biallelic loss of BCMA occurs in a relatively small fraction of MM, and the risk of this event can be increased by prior exposure to other anti-BCMA therapies—especially agents associated with chronic exposure (e.g. Belantamab). Here, TNFRSF17 is linked to Miyoshi myopathy.